The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Updates on advances in geriatric assessment and treatment in DLBCL for older patients
Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on advances in geriatric assessment and treatment in older patients with diffuse large B-cell lymphoma (DLBCL), noting significant progress since 2023, particularly in developing new agents such as bispecific antibodies for unfit older patients. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
You know, a lot has changed since 2023, all for the better. In 2023, I talked about how simplified geriatric assessment could really change practice and we are seeing that happen right now. Over the past three years, a lot of trials have been reported in older patients where they focus specifically on unfit older patients and patients who may not be good candidates for chemotherapy...
You know, a lot has changed since 2023, all for the better. In 2023, I talked about how simplified geriatric assessment could really change practice and we are seeing that happen right now. Over the past three years, a lot of trials have been reported in older patients where they focus specifically on unfit older patients and patients who may not be good candidates for chemotherapy. And we are trying new agents like bispecific antibodies in this space. And the culmination of this is that there’s a randomized Phase III trial called the Everglow study, which is going to pitch a combination of rituximab, polatuzumab and glofitamab against chemotherapy. So we don’t know if it will be successful, but I think it is huge in the advancement of this field.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
